Steven Prestrelski, PhD, MBA
Chief Scientific Officer & Cofounder
Dr. Steven Prestrelski is the Founder and Chief Scientific Officer of Xeris Pharmaceuticals. He is also the inventor of the Xeris platform technologies. Dr. Prestrelski is an internationally recognized expert in drug formulation and delivery, with over 30 years of drug development experience. Prior to joining Xeris, Dr. Prestrelski was Vice President of Pharmaceutical R&D at Amylin Pharmaceuticals. Previously, he was the Executive Director of the Bydureon® program at Amylin, leading this program from Phase 2 through global regulatory filings. Prior to Amylin, Dr. Prestrelski was Vice President, Biopharmaceuticals at PowderJect Technologies, Inc., where he pioneered the delivery of solid biopharmaceuticals. Dr. Prestrelski has also worked with Alza and Amgen in technical and management roles.
Dr. Prestrelski served on the Board of Directors of BaroFold, Inc. and on the Scientific Advisory Board of iMEDD, Inc., a Bay Area drug delivery company. Dr. Prestrelski has published over 60 invited book chapters and peer-reviewed journal articles and has over 30 issued (over 100 globally) and 40 pending patent applications in the field of drug development, formulation and delivery.
Dr. Prestrelski holds a PhD in Molecular Biophysics from the City University of New York and an MBA from the Rady School of Management at the University of California, San Diego.
Dr. Prestrelski served on the Board of Directors of BaroFold, Inc. and on the Scientific Advisory Board of iMEDD, Inc., a Bay Area drug delivery company. Dr. Prestrelski has published over 60 invited book chapters and peer-reviewed journal articles and has over 30 issued (over 100 globally) and 40 pending patent applications in the field of drug development, formulation and delivery.
Dr. Prestrelski holds a PhD in Molecular Biophysics from the City University of New York and an MBA from the Rady School of Management at the University of California, San Diego.